Compare VRTX & TT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRTX | TT |
|---|---|---|
| Founded | 1989 | 1885 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | EDP Services | Auto Parts:O.E.M. |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.7B | 94.1B |
| IPO Year | 2006 | 2009 |
| Metric | VRTX | TT |
|---|---|---|
| Price | $447.32 | $455.38 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 29 | 16 |
| Target Price | ★ $539.69 | $489.38 |
| AVG Volume (30 Days) | 1.1M | ★ 1.2M |
| Earning Date | 05-04-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 0.88% |
| EPS Growth | ★ 836.54 | 15.48 |
| EPS | ★ 4.02 | 2.62 |
| Revenue | $2,488,652,000.00 | ★ $14,782,000,000.00 |
| Revenue This Year | $10.79 | $12.12 |
| Revenue Next Year | $10.47 | $8.06 |
| P/E Ratio | ★ $111.69 | $172.95 |
| Revenue Growth | ★ 46.20 | 5.58 |
| 52 Week Low | $362.50 | $348.06 |
| 52 Week High | $509.98 | $503.47 |
| Indicator | VRTX | TT |
|---|---|---|
| Relative Strength Index (RSI) | 58.10 | 45.66 |
| Support Level | $429.02 | $403.18 |
| Resistance Level | $461.66 | $463.32 |
| Average True Range (ATR) | 11.30 | 9.96 |
| MACD | 1.65 | -2.20 |
| Stochastic Oscillator | 70.61 | 28.30 |
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Trane Technologies manufactures and services commercial and residential HVAC systems and transportation refrigeration solutions under its prominent Trane, American Standard, and Thermo King brands. The company generates approximately 70% of sales from equipment and 30% from parts and services. While the firm is domiciled in Ireland, North America accounts for approximately 80% of its revenue, with 13% from EMEA and 7% Asia-Pacific. The company was formed in 2020 when its former parent, Ingersoll Rand, merged with Gardner Denver in a tax-advantaged reverse Morris trust transaction.